ArticleFrontiers in endocrinology2026
Optimizing cardiovascular disease diagnosis through machine learning models integrating oxidized low-density lipoprotein and routine clinical indicators.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: To evaluate the diagnostic value of oxidized low-density lipoprotein cholesterol (oxLDL-C) for cardiovascular disease (CVD) and to construct a machine learning model integrating routine clinical indicators, thereby providing an efficient and economical tool to aid clinical diagnosis. Methods: This retrospective analysis enrolled 3, 686 participants. The discriminatory performance of oxLDL-C was compared with traditional lipid markers using receiver operating characteristic curves, and its association with CVD risk was analyzed using multivariate logistic regression. Through Recursive Feature Elimination and multivariate logistic regression, six core variables (including oxLDL-C) were ultimately selected. Seven machine learning algorithms were employed to construct predictive models, and their performance was evaluated in an internal validation set. Results: The discriminatory efficacy of oxLDL-C (AUC = 0.642) was significantly superior to traditional indicators such as low-density lipoprotein cholesterol. Its level was independently and positively associated with CVD risk (OR for the highest quartile = 3.773). The diagnostic model based on XGBoost demonstrated excellent discriminative ability (AUC = 0.911) and good calibration in internal validation. Discussion: The machine learning model integrating oxLDL-C with routine clinical indicators performs well, offering a practical tool for preliminary CVD risk screening and patient triage in resource-limited settings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.